This presentation focuses on the current and novel approaches used to develop drugs in the treatment of obesity. We’ll introduce the student to the physiological regulation of appetite and satiety in relation to meals, then we’ll provide an short overview of the previous and current treatment on the market for the treatment of obesity and finally we’ll describe some of the promising novel approaches pursued for future treatment.

Course responsible: Associate Professor Signe Sørensen Torekov, MD Nicolai Wewer Albrechtsen & Professor Jens Juul Holst

This presentation provides an overview of the existing treatment available for treatment of obesity. Genetic studies have revealed that the genes contributing to development of obesity is mainly located in the brain, therefore it would be logical to tro to target the brain when pursuing drugs for the treatment of obesity. However it’s not that simple.

Course responsible: Associate Professor Signe Sørensen Torekov, MD Nicolai Wewer Albrechtsen & Professor Jens Juul Holst

This presentation focus’ on the health benefits of being physically active and describes how physical training affects energy balance and metabolic health. Furthermore we’ll discuss the potential of physical training in prevention and treatment of obesity and diabetes and finally we’ll demonstrate methods that can be used to evaluate physical fitness, body fat distribution and insulin sensitivity.

Course responsible: Associate Professor Signe Sørensen Torekov, MD Nicolai Wewer Albrechtsen & Professor Jens Juul Holst

This presentation provides an introduction to physical activity and its influence on obesity, insulin resistance and diabetes type 2. Furthermore we’ll talk about how we can measure body fat distribution, insulin sensitivity and insulin resistance.

Course responsible: Associate Professor Signe Sørensen Torekov, MD Nicolai Wewer Albrechtsen & Professor Jens Juul Holst

This presentation talks about how it’s important to propagate the message that physical exercise has other health benefits effect than weight reduction and even if the body weight isn’t reduced by physical exercise, the body composition might change. Furthermore we’ll talk about the metabolic syndrome.

Course responsible: Associate Professor Signe Sørensen Torekov, MD Nicolai Wewer Albrechtsen & Professor Jens Juul Holst

This presentation aims to increase the students knowledge of physical inactivity and how it’s a major risk factor for developing diabetes, independent of body weight. Moreover we’ll discuss how we fight the global burden of a physical inactive lifestyle.

Course responsible: Associate Professor Signe Sørensen Torekov, MD Nicolai Wewer Albrechtsen & Professor Jens Juul Holst

This presentation talks about glucose regulation, how it’s possible to maintain a constant glucose level and physical regulation of plasma glucose. In continuation of this we’ll talk about diabetic complication, like neuropathy, retinopathy, nephropathy, chronic hyperglycemia, which can lead to myocardial infarction, stroke and amputations.

Course responsible: Associate Professor Signe Sørensen Torekov, MD Nicolai Wewer Albrechtsen & Professor Jens Juul Holst

This presentation provides an introduction to the islet hormones effects on various target tissues. Insulin is such a hormone, and in continuation of this, we’ll talk about the insulin receptor signaling. Furthermore we’ll talk about liver cells, fat cells, Lipogenesis, Insulin dose-response curves, C-peptide, Glucagon and glucagon producing tumor.

Course responsible: Associate Professor Signe Sørensen Torekov, MD Nicolai Wewer Albrechtsen & Professor Jens Juul Holst

This presentation focus' on glucose and insulin, and how these are integrated in the intact organism, in continuation of this we’ll talk about, insulin and glucagon secretion, hepatic glucose production and plasma glucose concentrations. The purpose of this is to get an understanding of what happens in the body when you have type 2 diabetes. Furthermore we’ll talk about the possibility of developing an glucagon receptor antagonist, regarding the therapy of diabetes.

Course responsible: Associate Professor Signe Sørensen Torekov, MD Nicolai Wewer Albrechtsen & Professor Jens Juul Holst

This presentation provides an introduction to diabetes (Type 1 and Type 2) development and how it’s a significant global burden. We’ll also discusses how stem cell based therapy can be used to treat diabetes and which advantages and disadvantages this treatments provides.

Course responsible: Associate Professor Signe Sørensen Torekov, MD Nicolai Wewer Albrechtsen & Professor Jens Juul Holst

This presentation provides an introduction to The Edmonton Protocol, which was published back in year 2000 from University of Edmonton. In continuation of this, we’ll talk about insulin injections and hypoglycemia.

Course responsible: Associate Professor Signe Sørensen Torekov, MD Nicolai Wewer Albrechtsen & Professor Jens Juul Holst

This presentation discusses the possibility of finding a cure for type 1 diabetes, and hereby developing a product, that maintains a normal blood glucose level without insulin treatment. In continuation of this, we’ll provide an introduction to beta cell replacement therapy based on The Edmonton Protocol, however we’ll be focusing on relying on stem cell technology rather than that of organ donor islets. Furthermore we’ll discuss how we can combine an encapsulation strategy, so we can avoid the use of immuno-suppression.

Course responsible: Associate Professor Signe Sørensen Torekov, MD Nicolai Wewer Albrechtsen & Professor Jens Juul Holst

In this presentation we’ll take a closer look at the relation between obesity and diabetes. Although it may seem simple, there are various aspects that make the relation between obesity and diabetes, more complex than at first sight.

Course responsible: Associate Professor Signe Sørensen Torekov, MD Nicolai Wewer Albrechtsen & Professor Jens Juul Holst

In this lecture we’ll discuss the role of inflammation in type 2 diabetes. In patients with type 2 diabetes, cardiovascular complications are of particular interest, as these are mainly responsible for the increase of mortality and obesity in diabetic patients compared with healthy subjects. In continuation of this and in order to understand why diabetes is an inflammatory disease, we’ll provide an introduction to the acute phase response.

Course responsible: Associate Professor Signe Sørensen Torekov, MD Nicolai Wewer Albrechtsen & Professor Jens Juul Holst

In this presentation we’ll translate our knowledge from genetics into clinically relevant patient stories. We’ll present case stories of translational metabolism, which means that we go from genotype to phenotype. Translational science is a multidisciplinary form of science that bridges the gap between basic science and applied science.

Course responsible: Associate Professor Signe Sørensen Torekov, MD Nicolai Wewer Albrechtsen & Professor Jens Juul Holst

In this presentation aim to increase the student’s knowledge about translational metabolism, in continuation of this we’ll elaborate on topics related to food ingestion, bone resorption, the intestinale hormone GIP, genetic variation in the receptor of GIP in relation to fracture risk, food availability and bone regulation, blood glucose and future treatment of osteoporosis.

Course responsible: Associate Professor Signe Sørensen Torekov, MD Nicolai Wewer Albrechtsen & Professor Jens Juul Holst

This presentation discuss how to treat hyperglycaemia in patients with type 2 diabetes. The cornerstone in the treatment is weight loss and increased physical activity, but most patients need pharmacological treatment from the time of diagnosis in order to control hyperglycemia. Furthermore we’ll discuss the use of all diabetic agents in patient with type 2 diabetes and how it’s important that the anti diabetic treatment is individualized.

Course responsible: Associate Professor Signe Sørensen Torekov, MD Nicolai Wewer Albrechtsen & Professor Jens Juul Holst

This presentation discuss the new antidiabetic agents. We have the incretin based therapy which include two groups of drugs, DDP-4 inhibitors and GLP-1 receptor agonist. Furthermore we’ll provide an introduction to the hormones GLP-1 and GIP and their effect on insulin.

Course responsible: Associate Professor Signe Sørensen Torekov, MD Nicolai Wewer Albrechtsen & Professor Jens Juul Holst

This presentation focuses on the treatment of hyperglycaemia with type 2 diabetes patients. We’ll provide an introduction to exenatide, liraglutide, GLP-1 receptor antagonist, combination therapy, DPP-4 inhibitor, pancreatic safety of incretin-based drugs, SGLT-2 inhibitor and glucose absorption.

Course responsible: Associate Professor Signe Sørensen Torekov, MD Nicolai Wewer Albrechtsen & Professor Jens Juul Holst

This presentation provides an introduction to Sodium-glucose linked transporter 2 inhibitors (SGLT-2) and how it affects the blood glucose. Furthermore we’ll discuss how SGLT-2 inhibitors can be used for treating patients with type 2 diabetes. Three SGLT-2 inhibitors have been approved: Dapa, Empa and Canagliflozin, for clinical use in patients with type 2 diabetes.

Course responsible: Associate Professor Signe Sørensen Torekov, MD Nicolai Wewer Albrechtsen & Professor Jens Juul Holst